VENICE, FL, - (http://www.financialnewsmedia.com News Alert) - Flameret (OTC Pink: FLRE) (PINKSHEETS: FLRE) announced today that it has launched Cannadol, a hemp oil rich in CBD (cannabidiol) which will be sold in 1 ounce bottles through its wholly-owned subsidiary Royal Hemp Corporation. The product is available immediately online on Royal Hemp's website (http://www.royalhempcorporation.com) and each bottle of Cannadol includes an organic hemp oil infused with 200mg of CBD. The product also includes about 1/10 of 1% THC (.1%), well beyond the legal threshold for THC content in the United States. The product will be marketed as a hemp oil dietary supplement rich in CBD and will be available for sale throughout the United States. The company is currently restricting sales outside of the United States. The product will be marketed through Royal Hemp Corporation, the company's recently announced Colorado wholly-owned subsidiary.
Unlike THC (the other prevalent cannabinoid), Cannabidiol is non-psychoactive while having the potential to possess a variety of therapeutic properties in many medical conditions including cancer, epilepsy, anxiety, pain and many others. THC and CBD have an inverse relationship, the more CBD, the less THC and the reverse also holds true.
Scientific and clinical studies continue to underscore CBD's potential (although unproven through scientific studies) as a possible treatment for a wide range of conditions, including rheumatoid arthritis, diabetes, alcoholism, MS, chronic pain, schizophrenia, PTSD, antibiotic-resistant infections, epilepsy, and other neurological disorders. CBD has demonstrated neuroprotective and neurogenic effects, and its anti-cancer properties are currently being investigated at several academic research centers in the United States and elsewhere. However, none of the statements regarding Cannadol or the potential therapeutic benefits of cannabidiol have been evaluated by the FDA.
John Meredith, Chief Executive Officer of Flameret, Inc. remarked, "We are thrilled that we can deliver this news to the marketplace. Flameret now has an exciting product available for purchase and we are cautiously optimistic about the commercial potential of Cannadol. We are now one of only a handful of companies in the world selling hemp oil rich in CBD and we will launch our second CBD product by the end of September 2014."
Mr. Meredith added, "We expect many calls from our shareholders and investors throughout the world asking about sales estimates on Cannadol. Although we expect significant interest, we will not provide any sales estimates at this time. We will be introducing an additional CBD product to the marketplace in September."
About Flameret
Flameret, Inc. has developed fire retardant products to suit a wide range of applications. These products are marketed under the brand names; Flameret, Flamex, Ultra Flamex and Impex. Flameret products are patented and held in the name of United American Inc.
The company is also in the process of launching a new line of products derived from industrial hemp. These products will be marketed under a wholly-owned subsidiary of Flameret, Inc.
About Royal Hemp Corporation
Royal Hemp Corporation is a Colorado corporation which was created to market and sell hemp based nutraceuticals, industrial products and consumer goods in the United States and throughout the world. All of the corporation's products will be legal to sell in all states in the United States and in many countries throughout the world.
The press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development program and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's products, the uncertainty of patent protection for the Company's intellectual property or trade secrets,and the Company's ability to obtain additional financing. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release.
Contact:
Flameret Inc
John Meredith:
jwsmeredith@aol.com
SOURCE Flameret , Inc.
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated one thousand four hundred dollars for news coverage of the current press release issued by Flameret, Inc. by a non-affiliated third party.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
My son was victim of a mental intriguing disorder called Schizophrenia unable to distinguish between fantasy and reality.And I have looked for solution, gave him Seroquel, Zyprexa and many medication but all this medication worsened the situation, All hope was lost before I met a man who directed me to where I got my medication.It is a herbal medication, It is really good for schizophrenia treatment, It is better than those I have been using over the years, there is no known side effect and my son is now improving as days passes by If you having such problem for advice and necessary solution, contact doson080@gmail.com
ReplyDeleteI decided to share this to help someone out there who is still held with schizophrenia.
ReplyDeletei suffered from chronic schizophrenia for 20 years and i have traveled round the world from one hospital to another neurologist and spent a lot of money, one day I took time to search internet which i found a lot of people thanking Dr. Nelson concerning the same problem and i discussed it with my wife and she said we should give a try so we order his product which i took for some months and am very much okay now.He is one of the Honest men out there. If you want to contact him on how to get his medicine or for info just reach him directly on drdavismartin62@gmail.com